Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-02-03 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the principles, structure, and management of compensation for the company's board members and senior executives. It references relevant laws and governance codes, and outlines the remuneration policy and procedures. There is no financial data or report content, but rather a detailed policy document on executive compensation. This matches the definition of Remuneration Information filings, which report compensation details for top executives and directors. The document length is 2101 characters, indicating it is a full policy document rather than a brief announcement or certification. Therefore, the appropriate classification is DEF 14A (Remuneration Information).
2026-02-03 Chinese
第四届董事会第二十一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of the resolutions passed at the 21st meeting of the 4th Board of Directors of Sailong Pharmaceutical Group Co., Ltd. It details the meeting's convening, attendance, and voting results on various internal governance matters such as amendments to insider information management and executive compensation policies. There is no financial data, earnings information, or report publication mentioned. The document is clearly about board meeting decisions and governance matters, not a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is a formal announcement of board resolutions, not a report or presentation.
2026-02-03 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a 2025年度业绩预告, which translates to '2025 Annual Performance Forecast' or 'Earnings Forecast'. It contains preliminary estimated financial results for the fiscal year 2025, including expected net loss, revenue, and other financial metrics. It explicitly states that the data is preliminary, unaudited, and subject to change pending the official audited annual report. The document also discusses risks related to auditor resignation and potential delisting risks. The length is 3350 characters, which is relatively short and the document is primarily an earnings forecast rather than a full annual report or audited financial statements. It is not a report publication announcement because it contains substantive financial data and detailed forecast information, not just a notice of report availability. It is not a certification or regulatory filing. The document is best classified as an Earnings Release (ER) because it announces key financial results and outlook for the fiscal year, even though it is a forecast rather than final audited results. FY 2025
2026-01-30 Chinese
关于收到独立董事关于督促公司妥善处理会计师事务所辞任事宜及完善相关治理工作函的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company regarding receipt of a letter from independent directors urging the company to properly handle the resignation of auditing firms and improve governance. It discusses governance concerns, audit firm resignations, and recommendations for management actions. The document does not contain any financial statements, audit reports, or detailed financial data. It is a regulatory announcement about governance and audit-related issues, not a full audit report or annual report. The document length is short (1761 characters), and it is an announcement of a governance-related matter. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-01-30 Chinese
关于公司股票可能被终止上市的风险提示公告
Regulatory Filings Classification · 95% confidence The document is a risk warning announcement regarding the potential delisting of the company's stock due to financial performance issues and audit firm resignation. It references regulatory rules about delisting risk warnings and the company's obligation to disclose such risk notices periodically before the annual report is published. The document does not contain actual audited financial statements or detailed financial data but rather a risk disclosure and preliminary financial estimates. It is a formal announcement about the risk of stock delisting, not the delisting itself or a full financial report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory disclosure about risk and compliance rather than a full report or a delisting notice.
2026-01-30 Chinese
关于2025年度审计会计师事务所辞任的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the resignation of the auditing accounting firm for the company's 2025 fiscal year audit. It details the resignation letter from the auditor, the company's response, and risk warnings related to the audit and potential delisting risks. The document does not contain any financial statements or audit results itself, but rather informs about the change in auditor and related procedural matters. This fits the category of an Audit Report / Information announcement specifically about auditor resignation, which is a standalone audit-related announcement but not a full audit report or annual report. Therefore, the appropriate classification is AR (Audit Report / Information). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear context and content. FY 2025
2026-01-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.